Post-earnings recap
Reported
Thu, Nov 7, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that 10X Genomics is still in a development phase, as reflected in the negative EPS. Despite missing on EPS, the stock rose by 2.26%, likely due to positive sentiment around management's focus on innovation. Investors may be optimistic about the company's long-term prospects, even without specific guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management remains focused on innovation and believes in their long-term growth potential. However, they did not provide specific guidance for future quarters.
Management highlighted ongoing investment in innovation and product development.
They expressed confidence in their long-term growth strategy despite current challenges.